News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2010 Archives

Dec 12, 2010
Phase 2 Data Presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium

Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual...

More
Nov 13, 2010
NKTR-181 Shows Reduced Abuse Potential and CNS Side Effects in Preclinical Models

Nektar Therapeutics (Nasdaq: NKTR) today presented two poster presentations during the Blood-Brain Barrier Session at the Society for Neuroscience 40th Annual Meeting in San Diego, CA. New data...

More
Nov 4, 2010

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2010. Cash, cash equivalents, and short-term investments at September 30, 2010...

More
Oct 28, 2010

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010, after the close of U.S.-based financial...

More
Oct 17, 2010
Studies Demonstrate NKTR-181 Has Reduced Abuse Liability with Equivalent Analgesia to Oxycodone in Preclinical Models of Abuse and Pain

Nektar Therapeutics (Nasdaq: NKTR) today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability...

More
Oct 15, 2010
Preclinical Data Presented in Oral Abstract Presentation at Pain 2010 Conference

Nektar Therapeutics (Nasdaq: NKTR) presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is...

More
Sep 17, 2010

Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2010 Global Life Sciences Conference in New York at the...

More
Jul 28, 2010

Nektar Therapeutics today reported its financial results for the second quarter ended June 30, 2010. Cash, cash equivalents, and short-term investments at June 30, 2010 were $338.2 million as...

More
Jul 21, 2010

Nektar Therapeutics will announce its financial results for the second quarter ended June 30, 2010 on Wednesday, July 28, 2010, after the close of U.S.-based financial markets. Howard Robin,...

More
Jul 6, 2010

Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's...

More
Jun 24, 2010

Nektar Therapeutics announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in...

More
Jun 9, 2010

Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer...

More
Jun 6, 2010
Phase 2 Data Highlighted in Oral Abstract Session of 2010 American Society of Clinical Oncology Annual Meeting

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68...

More
Jun 3, 2010

Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2010 Global Life Sciences Conference at The Grand Hyatt New York on Wednesday,...

More
May 20, 2010
NKTR-105 Phase 1 Clinical Trial To Be Presented in New Trials in Progress Session

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract...

More
May 5, 2010

Nektar Therapeutics today reported its financial results for the first quarter ended March 31, 2010. Cash, cash equivalents, and short-term investments at March 31, 2010 were $362.0 million as...

More
Apr 27, 2010

Nektar Therapeutics will announce its financial results for the first quarter ended March 31, 2010 on Wednesday, May 5, 2010, after the close of U.S.-based financial markets. Howard Robin,...

More
Mar 8, 2010

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women...

More
Mar 2, 2010

Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the 30th Annual Cowen and Company Healthcare Conference at The Boston Marriott Copley Place...

More
Mar 2, 2010

Nektar Therapeutics today reported its financial results for the fourth quarter and year ended December 31, 2009. Cash, cash equivalents, and short-term investments at December 31, 2009 increased...

More
Feb 23, 2010

Nektar Therapeutics will announce its financial results for the fourth quarter and year ended December 31, 2009 on Tuesday, March 2, 2010, after the close of U.S.-based financial markets. Howard...

More
Feb 2, 2010

Nektar Therapeutics today announced that R. Scott Greer has joined the company's Board of Directors. Mr. Greer is an accomplished industry leader with more than 25 years of experience in the...

More
Jan 12, 2010

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first...

More
Jan 6, 2010

Nektar Therapeutics today announced the appointment of Stephen K. Doberstein, Ph.D., to the position of Senior Vice President and Chief Scientific Officer. Dr. Doberstein will report to Nektar's...

More
Jan 6, 2010

Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 28th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide